NRx Pharmaceuticals (NASDAQ: NRXP) shares have jumped premarket after the announcement of a collaboration with IQVIA (NYSE: IQV).
The collaboration will see IQVIA provide pharmacovigilance services and medical information in preparation for potential regulatory actions for a COVID-19 treatment.
It will allow NRx to access IQVIA’s domain experience with COVID-19, as well as its data assets and analytics to support potential emergency use authorization (EUA) of NRx's investigational product ZYESAMI.
“As a small biopharma company preparing to launch a lifesaving medicine across multiple countries, we deeply appreciate the global reach that IQVIA is able to offer in support of patients, families, and those who care for them,” commented Robert Besthof, chief commercial officer and head of Operations of NRx.
Susan Kitlas, vice president, Precommercial Business Unit at IQVIA, commented: “We are honored by the opportunity to join with NRx on the EUA activation and compliance for ZYESAMI in treating some of the sickest patients suffering from COVID-19.”
“IQVIA’s experience and expertise within the COVID-19 market will be a valuable component in helping make this treatment more widely available.”
NRx shares are trading at $12.08 premarket, up over 10%. IQVIA's shares are unmoved, sitting at $255.57.
Should You Invest in NRx Pharmaceuticals Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now